BiotechTube
FLAG Therapeutics

FLAG Therapeutics

Durham, United States· Est.
flagtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20.0M

Overview

FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.

Oncology

Technology Platform

Three proprietary drug discovery platforms for developing water-soluble, multi-acting small molecule therapeutics: 1) Anti-Angiogenic/Tubulin Inhibitors for vascularized tumors (enables BBB penetration), 2) FR-α/GARFTase Inhibitors for FR-α overexpressing tumors, 3) FR-α/SHMT-2 Inhibitors for FR-α overexpressing tumors.

Funding History

4
Total raised:$20.0M
Series A$15M
Seed$3.5M
Grant$713K
Grant$787K

Opportunities

The profound unmet need in its target cancers, particularly DIPG, offers opportunities for regulatory incentives like Orphan Drug and Pediatric Rare Disease designations, which can accelerate development and provide market exclusivity.
The multi-action, platform-based approach could yield best-in-class single agents for multiple solid tumors, creating significant partnership potential with larger oncology-focused biopharma companies.

Risk Factors

High risk of clinical failure as promising preclinical data may not translate to human safety or efficacy, especially in the fragile DIPG patient population.
The company is financially vulnerable, requiring a major funding round to initiate clinical trials in 2026, and operates in a competitive landscape where other novel modalities are also being explored for these cancers.

Competitive Landscape

FLAG operates in highly competitive spaces: DIPG/GBM has numerous academic and biotech efforts exploring targeted therapies, immunotherapies, and drug delivery technologies. In FR-α targeting, competitors include antibody-drug conjugates (e.g., Elahere for ovarian cancer) and other small molecules. FLAG's differentiation lies in its dual-action small molecule approach designed for blood-brain barrier penetration and improved tolerability.

More companies in Oncology (General) →More companies in United States →